Update on the treatment of cutaneous T-cell lymphoma (CTCL): Focus on vorinostat.
Epigenetic regulation of gene transcription by small molecule inhibitors of histone deacetylases (HDAC) is a novel cancer therapy. Vorinostat (Zolinza()) is the first FDA approved HDAC-inhibitor for treatment of patients with cutaneous T cell lymphoma (CTCL) who have progressive, persistent or recurrent disease on or following two systemic therapies. Vorinostat was active against solid tumors and hematologic malignancies as intravenous and oral preparations in Phase I development. In two Phase II trials, vorinostat was safe and effective at an oral dose of 400 mg/day with an overall response rate of 24%-30% in refractory advanced patients with CTCL including large cell transformation and Sézary syndrome (SS). The common side effects of vorinostat, similar in all studies, included gastro-intestinal symptoms, fatigue, and thrombocytopenia and the most common serious events were thrombosis. Vorinostat, in combination with other agents such as radiation therapy and chemotherapy, have shown synergistic or additive effects in a variety of cancers in clinical trials.
Duvic
Madeleine
M
The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Vu
Jenny
J
Exp Hematol. 2005 Jan;33(1):53-61
15661398
Blood. 2003 Apr 15;101(8):3236-9
12446442
Nat Biotechnol. 2007 Jan;25(1):84-90
17211407
J Clin Invest. 2005 Apr;115(4):798-812
15841167
Leukemia. 2002 Jul;16(7):1331-43
12094258
J Cell Biochem. 2004 May 15;92(2):223-37
15108350
Oncogene. 1999 Nov 25;18(50):7016-25
10597302
Anticancer Res. 2003 Jan-Feb;23(1A):499-503
12680257
Nat Clin Pract Oncol. 2005 Mar;2(3):150-7
16264908
Eur J Haematol. 2006 Jan;76(1):42-50
16343270
N Engl J Med. 2004 May 6;350(19):1978-88
15128898
Arch Dermatol. 2002 Mar;138(3):325-32
11902983
J Cancer Res Clin Oncol. 2005 Jun;131(6):385-94
15754201
Cancer Treat Rev. 2004 Aug;30(5):461-72
15245778
Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):3003-7
9501205
Cancer. 1981 Jan 1;47(1):207-14
7459811
Leuk Lymphoma. 2004 Sep;45(9):1755-65
15223633
J Am Acad Dermatol. 2004 Apr;50(4):600-7
15034511
Eur J Haematol Suppl. 2005 Jul;(66):150-8
16007885
Blood. 2008 Feb 1;111(3):1060-6
17962510
Dermatology. 2003;206(2):142-7
12592082
Nat Rev Drug Discov. 2006 Sep;5(9):769-84
16955068
BMC Biol. 2006 Aug 02;4:24
16884538
J Clin Invest. 2001 Nov;108(9):1321-30
11696577
Biochem J. 2003 Mar 15;370(Pt 3):737-49
12429021
Hematol Oncol Clin North Am. 1995 Oct;9(5):1117-26
8522488
J Am Acad Dermatol. 2005 Feb;52(2):275-80
15692473
Nat Rev Cancer. 2001 Dec;1(3):194-202
11902574
J Clin Oncol. 2001 Jan 15;19(2):376-88
11208829
J Clin Oncol. 2005 Jun 10;23(17):3923-31
15897550
Annu Rev Biochem. 2004;73:417-35
15189148
Leukemia. 2004 Jul;18(7):1288-95
15141228
Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):673-8
15637150
Int J Cancer. 2006 Jul 1;119(1):221-8
16450389
Proc Natl Acad Sci U S A. 2004 Feb 3;101(5):1241-6
14734806
Expert Opin Ther Targets. 2004 Oct;8(5):409-22
15469392
Expert Opin Investig Drugs. 2000 Dec;9(12):2923-34
11093362
Blood. 2004 Jun 15;103(12):4636-43
14996704
Curr Pharm Des. 2004;10(19):2289-98
15279609
Blood. 2005 Jul 15;106(2):454-7
15811959
Blood. 1997 Jan 1;89(1):32-40
8978274
Mol Cancer Ther. 2003 Dec;2(12):1273-84
14707268
Proc Natl Acad Sci U S A. 2004 Mar 16;101(11):3921-6
15001702
Expert Opin Investig Drugs. 2005 Dec;14(12):1497-511
16307490
Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):10014-9
10954755
Int J Dermatol. 2003 Mar;42(3):238-41
12653924
Clin Exp Immunol. 1997 Jan;107 Suppl 1:16-20
9020930
J Mol Biol. 2004 Apr 16;338(1):17-31
15050820
Anticancer Res. 1999 Nov-Dec;19(6B):4999-5005
10697502
JAMA. 1992 Mar 11;267(10):1354-8
1740857
Cell Cycle. 2004 Jun;3(6):779-88
15153801
J Invest Dermatol. 1996 Sep;107(3):373-6
8751973
Br J Dermatol. 2006 Aug;155(2):261-6
16882161
Blood. 2007 Jan 1;109(1):31-9
16960145
Int J Cancer. 2006 Aug 15;119(4):944-54
16550602
Curr Opin Hematol. 2005 Jul;12(4):273-8
15928483
Anticancer Res. 2002 May-Jun;22(3):1497-504
12168829
J Invest Dermatol. 2005 Nov;125(5):1045-52
16297208
Curr Med Chem Anticancer Agents. 2005 Sep;5(5):529-60
16178777
Cancer Res. 2004 Apr 1;64(7):2580-9
15059915
Am J Clin Pathol. 2005 Apr;123(4):510-5
15743738
Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11700-5
12189205
Blood. 2002 Nov 1;100(9):3369-73
12384439
Br J Dermatol. 1995 Jul;133(1):6-12
7669641
J Clin Oncol. 2007 Jul 20;25(21):3109-15
17577020
Int J Oncol. 2004 Dec;25(6):1509-19
15547685
Cancer Res. 2002 Sep 1;62(17):4916-21
12208741
J Eur Acad Dermatol Venereol. 2004 Jul;18(4):397-415
15196152
Cell Cycle. 2005 Apr;4(4):549-51
15738652
J Invest Dermatol. 2005 Apr;124(4):741-50
15816832
Arch Dermatol. 2005 Sep;141(9):1176-8
16172331
Br J Cancer. 2000 Sep;83(6):817-25
10952788
Proc Natl Acad Sci U S A. 2004 Dec 28;101(52):18030-5
15596714
Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3578-88
14506144
Br J Dermatol. 1974 Dec;91(6):607-16
4281316
Int J Cancer. 2001 Apr 15;92(2):226-31
11291050
Cancer Res. 2000 Sep 15;60(18):5165-70
11016644
J Clin Oncol. 2006 Jan 1;24(1):166-73
16330674
Blood. 2001 Nov 1;98(9):2865-8
11675364
Arch Dermatol. 2001 May;137(5):581-93
11346336
Blood. 2002 Apr 15;99(8):2929-39
11929784